Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EXG111
- Development stage
- Preclinical
- Lead developer
- Exegenesis Bio
- Modality
- Gene Therapies
- Administration
- Intravenous
01
Overview
EXG111 is an investigational gene therapy being developed by Exegenesis Bio for the treatment of Duchenne Muscular Dystrophy (DMD). The therapy is designed to restore the expression and function of dystrophin, a critical structural protein in muscle fibers that is deficient in patients with DMD due to mutations in the DMD gene. By delivering a functional version of the gene or a micro-dystrophin construct, EXG111 aims to stabilize muscle cell membranes and slow the progressive muscle degeneration characteristic of the disease. Administered via intravenous (IV) infusion, the program is currently in the IND-enabling stage of development as of early 2026.
02
Targets
DMD (Dystrophin)
Beyond the preview
Go deeper on EXG111.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EXG111.